Onslow Memo­r­i­al Hos­pi­tal is part of a nation­al net­work of top ImPACT health­care providers

ImPACT (Immediate Post-Concussion Assessment and Cognitive Testing), a scientifically-validated computerized neurocognitive concussion management tool, is the first medical device of its kind to receive U.S. Food and Drug Administration (FDA) de novo clearance.

Earlier this year, Dr. Scott Playford, MD, MBA, of the Sports Medicine Clinic of Onslow Memorial Rehabilitation Center, and Onslow Primary Care and Sports Medicine, earned the designation of Credentialed ImPACT Consultant™(CIC) by completing specialized training.

"ImPACT's FDA clearance is a huge step forward for the industry, for athletes and others who are at-risk of concussion-related injuries, as well as for licensed, trained medical professionals everywhere," said Michael Wahlster, Chief Executive Officer of ImPACT Applications.

"ImPACT Applications has a proven commitment to science, research, and innovation. That is why a global network of hospitals, clinics, youth sports organizations, and professional athletes utilize and trust ImPACT," Wahlster stated.

Dr. Playford’s CIC status enables him to administer ImPACT baseline and post-injury testing for patients 12 years of age and older, including recreational and serious athletes, as well as non-athletes, and to offer those patients a full continuum of clinical concussion management and care.

“Experts agree that neurocognitive testing is an important tool in effective concussion assessment and management, and this designation by the FDA validates ImPact as one of the best computerized neurocognitive testing tools available to us right now. So I’m proud to be part of their network of consultants,” Dr. Playford said.

“Better management of concussions early in the process may help athletes return to play sooner–and most importantly, it may help prevent long term complications,” he added.